Catalyst calendar
What Cambridge is waiting on.
Every expected clinical readout and disclosed FDA decision date for listed biotechs in the cluster, in order, each one shown against the cash the company has to reach it. Extension, rollover and healthy-volunteer studies are excluded, because they are not the events anyone is waiting for.
- Catalysts in the next 18 months
- 142
- across 58 companies
- FDA decision dates
- 12
- disclosed in company filings
- Where cash runs out first
- 2
- companies, at their next catalyst
- Active trials tracked
- 361
- 81 companies sponsoring
Q4 2026
24 catalysts- Nov2026Cash past the catalyst
$1.13B cash · 24 mo runway
- Nov2026Cash past the catalyst
$193M cash · 17 mo runway
- Nov2026
estimated
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Pulmonary Hypertension · Heart Failure With Preserved Ejection Fraction
NCT06616974Cash past the catalyst$227M cash · 38 mo runway
- Nov2026
estimated
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Eye Cancer · Primary Cancer
NCT06643884Cash past the catalyst$324M cash · 38 mo runway
- Nov2026Cash past the catalyst
$792M cash · 31 mo runway
- Nov2026
estimated
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
Glycogen Storage Disease
NCT05095727Cash past the catalyst$6.91B cash · 60+ mo runway
- Nov2026
estimated
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Advanced Solid Tumor
NCT04735978Cash past the catalyst$308M cash · 15 mo runway
- Nov2026
estimated
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
Duchenne Muscular Dystrophy
NCT03368742Cash past the catalyst$349M cash · 21 mo runway
- Nov2026Self-funding
$9.82B cash · Self-funding runway
- Dec2026
estimated
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
Lupus Nephritis · Autoimmune Diseases · Systemic Sclerosis (SSc)
NCT06375993Cash past the catalyst$118M cash · 17 mo runway
- Dec2026
estimated
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
HEPATITIS C VIRUS CHRONIC INFECTION · Hepatitis C, Chronic · Hepatitis C Virus Infection
NCT07037277Cash past the catalyst$219M cash · 17 mo runway
- Dec2026
estimated
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Idiopathic Pulmonary Fibrosis (IPF)
NCT07194382Cash past the catalyst$414M cash · 52 mo runway
- Dec2026
estimated
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Lymphoblastic Lymphoma · T-Cell Lymphoblastic Leukemia/Lymphoma · Lymphoblastic Leukemia
NCT05885464Cash past the catalyst$1.04B cash · 32 mo runway
- Dec2026
estimated
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Antibody-mediated Rejection
NCT06685757Self-funding$1.30B cash · Self-funding runway
- Dec2026
estimated
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Non Small Cell Lung Cancer · Triple Negative Breast Cancer · Hodgkin Lymphoma
NCT06150664Cash past the catalyst$180M cash · 38 mo runway
- Dec2026
estimated
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
RSV Infection · RSV · Respiratory Syncytial Virus (RSV)
NCT07482657Cash past the catalyst$190M cash · 60+ mo runway
- Dec2026
estimated
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022Cash past the catalyst$65.1M cash · 12 mo runway
- Dec2026
estimated
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
NCT02227251Cash past the catalyst$65.1M cash · 12 mo runway
- Dec2026
estimated
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
Epileptic Encephalopathy · SCN2A Encephalopathy
NCT07019922Cash past the catalyst$1.37B cash · 54 mo runway
- Dec2026
estimated
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
Developmental and Epileptic Encephalopathy 1
NCT07010471Cash past the catalyst$1.37B cash · 54 mo runway
- Dec2026Cash past the catalyst
$1.37B cash · 54 mo runway
- Dec2026Cash past the catalyst
$792M cash · 31 mo runway
- Dec2026
estimated
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Head and Neck Cancer · Cervical Cancer · Non-small Cell Carcinoma
NCT05973487Cash past the catalyst$100M cash · 10 mo runway
- Dec2026
estimated
Self-funding$934M cash · Self-funding runway
Q1 2027
23 catalysts- Jan2027
estimated
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
Focal Epilepsy
NCT07505004Cash past the catalyst$1.37B cash · 54 mo runway
- Jan2027
estimated
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
Neovascular Age-related Macular Degeneration
NCT06495918Cash past the catalyst$599M cash · 30 mo runway
- Jan2027Cash past the catalyst
$1.13B cash · 24 mo runway
- Jan2027
FDA target action date (PDUFA)
8-K filed Aug 6, 2026Cash past the catalyst$1.37B cash · 54 mo runway
- Feb2027Cash past the catalyst
$907M cash · 33 mo runway
- Feb2027
estimated
Cash past the catalyst$768M cash · 60+ mo runway
- Feb2027
estimated
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Prostate Cancer Patients Treated by Radiotherapy · Prostate Cancer (Adenocarcinoma)
NCT07332000Cash past the catalyst$202M cash · 43 mo runway
- Feb2027
estimated
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Myotonic Dystrophy Type 1 (DM1)
NCT06185764Self-funding$9.82B cash · Self-funding runway
- Feb2027
estimated
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
Acute Gastroenteritis · Norovirus Acute Gastroenteritis
NCT06592794Cash past the catalyst$6.91B cash · 60+ mo runway
- Feb2027Self-funding
$173M cash · Self-funding runway
- Mar2027
estimated
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Non-muscle-invasive Bladder Cancer · NMIBC · Non-Muscle Invasive Bladder Carcinoma
NCT05483868Cash past the catalyst$324M cash · 38 mo runway
- Mar2027
estimated
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Intrahepatic Cholangiocarcinoma (Icc) · Cholangiocarcinoma · Other Solid Tumors, Adult
NCT06777316Cash past the catalyst$792M cash · 31 mo runway
- Mar2027
estimated
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Non-Proliferative Diabetic Retinopathy
NCT07235085Cash past the catalyst$599M cash · 30 mo runway
- Mar2027
estimated
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Myotonic Dystrophy 1
NCT06667453Cash past the catalyst$117M cash · 20 mo runway
- Mar2027
estimated
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD) · Major Depressive Disorder With Anxious Distress
NCT07065240Cash past the catalyst$404M cash · 57 mo runway
- Mar2027
estimated
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Dravet Syndrome
NCT06872125Cash past the catalyst$359M cash · 20 mo runway
- Mar2027
estimated
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Generalized Myasthenia Gravis
NCT06456580Cash past the catalyst$482M cash · 48 mo runway
- Mar2027
estimated
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
Cytomegalovirus Infection
NCT05683457Cash past the catalyst$6.91B cash · 60+ mo runway
- Mar2027Cash past the catalyst
$628M cash · 22 mo runway
- Mar2027
estimated
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Hypothalamic Obesity · Multiple Pituitary Hormone Deficiency Genetic Form · Septo-Optic Dysplasia
NCT06760546Cash past the catalyst$321M cash · 47 mo runway
- Mar2027
estimated
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathic Pain
NCT06619860Self-funding$9.82B cash · Self-funding runway
- Mar2027
estimated
Cash past the catalyst$118M cash · 17 mo runway
- Mar2027
estimated
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Non Small Cell Lung Cancer · Glioma Glioblastoma Multiforme · Glioma, Malignant
NCT06810544Cash past the catalyst$1.01B cash · 60+ mo runway
Q2 2027
32 catalysts- Apr2027
estimated
Cash past the catalyst$65.1M cash · 12 mo runway
- Apr2027
estimated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Cancer · Colorectal Cancer · Solid Tumor
NCT05919264Cash past the catalyst$1.12B cash · 60+ mo runway
- Apr2027
estimated
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathic Pain
NCT07231419Self-funding$9.82B cash · Self-funding runway
- Apr2027
estimated
Cash to the catalyst, barely$55.6M cash · 9.4 mo runway
- Apr2027
estimated
Self-funding$3.59B cash · Self-funding runway
- Apr2027
estimated
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
PIK3CA Mutation · Solid Tumor, Adult · HER2-negative Breast Cancer
NCT05216432Cash past the catalyst$849M cash · 48 mo runway
- May2027
estimated
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
Asthma · COPD (Chronic Obstructive Pulmonary Disease)
NCT07116889Cash past the catalyst$457M cash · 23 mo runway
- May2027
estimated
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Myelofibrosis; Anemia · Anemia · Myelofibrosis
NCT05320198Cash past the catalyst$683M cash · 43 mo runway
- May2027
estimated
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Obesity
NCT07458269Cash past the catalyst$1.04B cash · 40 mo runway
- May2027
estimated
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Duchenne Muscular Dystrophy
NCT06138639Cash past the catalyst$349M cash · 21 mo runway
- May2027Cash past the catalyst
$647M cash · 32 mo runway
- May2027
estimated
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM)
NCT07465224Self-funding$3.59B cash · Self-funding runway
- May2027
estimated
Cash past the catalyst$90.0M cash · 17 mo runway
- May2027
estimated
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
NCT05881408Self-funding$934M cash · Self-funding runway
- May2027
estimated
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathic Pain
NCT06628908Self-funding$9.82B cash · Self-funding runway
- Jun2027
estimated
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
NCT07268638Self-funding$159M cash · Self-funding runway
- Jun2027
estimated
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis · Progressive Pulmonary Fibrosis · Pulmonary Fibrosis Secondary to Systemic Sclerosis
NCT06329401Cash past the catalyst$414M cash · 52 mo runway
- Jun2027
estimated
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Advanced Urothelial Cancer · Metastatic Urothelial Carcinoma
NCT07484022Cash past the catalyst$457M cash · 23 mo runway
- Jun2027
estimated
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Advanced Solid Tumor · Pancreatic Adenocarcinoma · Malignant Melanoma (Cutaneous)
NCT05585320Cash past the catalyst$166M cash · 32 mo runway
- Jun2027
estimated
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Sickle Cell Disease
NCT07187973Cash past the catalyst$683M cash · 43 mo runway
- Jun2027
estimated
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Myelofibrosis · Moderate Thrombocytopenia · Mild Thrombocytopenia
NCT05980806Cash to the catalyst, barely$65.1M cash · 12 mo runway
- Jun2027
estimated
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
NCT07217015Cash past the catalyst$1.65B cash · 60+ mo runway
- Jun2027
estimated
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Catecholaminergic Polymorphic Ventricular Tachycardia
NCT07148089Cash past the catalyst$349M cash · 21 mo runway
- Jun2027
estimated
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Ulcerative Colitis · Inflammatory Bowel Diseases · Colitis
NCT07012395Cash past the catalyst$1.07B cash · 52 mo runway
- Jun2027
estimated
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · NSCLC
NCT06922591Cash past the catalyst$1.01B cash · 60+ mo runway
- Jun2027
estimated
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Locally Advanced Solid Tumor
NCT05732831Cash past the catalyst$1.01B cash · 60+ mo runway
- Jun2027
estimated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
NCT07659782Cash to the catalyst, barely$136M cash · 10 mo runway
- Jun2027
estimated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Colorectal Cancer
NCT07659795Cash to the catalyst, barely$136M cash · 10 mo runway
- Jun2027
estimated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC) · G12D Mutated KRAS
NCT07644559Cash to the catalyst, barely$136M cash · 10 mo runway
- Jun2027
estimated
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
Sickle Cell Disease · Hydroxyurea Failure · Hydroxyurea Intolerance
NCT05329649Self-funding$9.82B cash · Self-funding runway
- Jun2027
estimated
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Beta-Thalassemia · Thalassemia · Hematologic Diseases
NCT05477563Self-funding$9.82B cash · Self-funding runway
- Jun2027
estimated
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Von Willebrand Disease (VWD) · Heavy Menstrual Bleeding (HMB)
NCT07575308Self-funding$3.59B cash · Self-funding runway
Q3 2027
18 catalysts- Jul2027
estimated
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
Von Willebrand Disease (VWD) · Von Willebrand Disease (VWD), Type 1 · Von Willebrand Disease (VWD), Type 2
NCT06754852Cash past the catalyst$457M cash · 60+ mo runway
- Jul2027
estimated
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic Malignancy · Refractory Hematologic Malignancy · Relapsed Primary Central Nervous System Lymphoma
NCT03328078Cash runs out first$5.1M cash · 2.0 mo runway
- Jul2027
estimated
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Polycythemia Vera (PV)
NCT06985147Cash past the catalyst$683M cash · 43 mo runway
- Jul2027
estimated
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Neuromuscular Disease · Neuromuscular Diseases (NMD) · Neurodegenerative Disease
NCT06672237Cash past the catalyst$628M cash · 22 mo runway
- Jul2027
estimated
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
Obesity · Overweight
NCT07497880Cash past the catalyst$1.04B cash · 40 mo runway
- Jul2027
estimated
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT07161037Self-funding$9.82B cash · Self-funding runway
- Aug2027
estimated
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
Glanzmann Thrombasthenia
NCT06211634Cash past the catalyst$457M cash · 60+ mo runway
- Aug2027
estimated
Self-funding$710M cash · Self-funding runway
- Aug2027
estimated
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
Advanced Solid Tumors
NCT06880549Cash past the catalyst$6.91B cash · 60+ mo runway
- Aug2027
estimated
Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
NCT04856982Self-funding$1.30B cash · Self-funding runway
- Aug2027
estimated
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
NCT06393712Self-funding$3.59B cash · Self-funding runway
- Aug2027
estimated
Cash past the catalyst$90.0M cash · 17 mo runway
- Aug2027
estimated
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer · Cholangiocarcinoma · Gall Bladder Cancer
NCT05506943Cash past the catalyst$180M cash · 38 mo runway
- Aug2027
estimated
Cash past the catalyst$6.91B cash · 60+ mo runway
- Sep2027
estimated
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
NCT05608044Cash runs out first$18.7M cash · 2.3 mo runway
- Sep2027
estimated
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
Alpha-1 Antitrypsin Deficiency
NCT06405633Cash past the catalyst$431M cash · 25 mo runway
- Sep2027
estimated
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Neutropenia
NCT06056297Cash past the catalyst$188M cash · 30 mo runway
- Sep2027
estimated
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma · Metastatic Hepatocellular Carcinoma
NCT06600321Self-funding$3.59B cash · Self-funding runway
Q4 2027
25 catalysts- Oct2027
estimated
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Castration-Resistant Prostate Cancer (CRPC) · Castration-Resistant Prostate Cancer · Prostate Cancer
NCT07745361Cash past the catalyst$578M cash · 42 mo runway
- Oct2027
estimated
Cash past the catalyst$461M cash · 45 mo runway
- Oct2027
estimated
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Hidradenitis Suppurativa (HS)
NCT07766005Cash past the catalyst$1.07B cash · 52 mo runway
- Oct2027
estimated
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Chronic Obstructive Pulmonary Disease
NCT06981078Cash past the catalyst$261M cash · 23 mo runway
- Oct2027
estimated
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of Anal Canal · Colorectal Cancer
NCT04429542Cash past the catalyst$497M cash · 44 mo runway
- Nov2027
estimated
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
Congenital Factor VII Deficiency
NCT07347249Cash past the catalyst$457M cash · 60+ mo runway
- Nov2027
estimated
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Chronic Lymphocytic Leukemia · B-cell Malignancies
NCT07271667Cash runs out first$5.1M cash · 2.0 mo runway
- Nov2027
estimated
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Beta-Thalassemia · Thalassemia · Genetic Diseases, Inborn
NCT05356195Self-funding$9.82B cash · Self-funding runway
- Nov2027
estimated
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Choroidal Melanoma · Indeterminate Lesions · Uveal Melanoma
NCT06007690Cash past the catalyst$324M cash · 38 mo runway
- Nov2027
estimated
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Solid Tumors
NCT03313778Cash past the catalyst$6.91B cash · 60+ mo runway
- Nov2027
estimated
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Huntington's Disease
NCT07536061Self-funding$934M cash · Self-funding runway
- Dec2027
estimated
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
Castration Resistant Metastatic Prostate Cancer · Prostate Cancer · mCRPC (Metastatic Castration-resistant Prostate Cancer)
NCT07581184Cash past the catalyst$517M cash · 60+ mo runway
- Dec2027
estimated
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Urothelial Carcinoma Bladder · Triple Negative Breast Cancer (TNBC) · Hormone Receptor Positive Breast Adenocarcinoma
NCT07020117Cash past the catalyst$517M cash · 60+ mo runway
- Dec2027
estimated
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Eosinophilic Asthma
NCT07323654Cash past the catalyst$1.65B cash · 60+ mo runway
- Dec2027
estimated
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Negative Symptoms of Schizophrenia
NCT07565428Cash past the catalyst$75.3M cash · 35 mo runway
- Dec2027
estimated
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
NCT06128629Cash past the catalyst$628M cash · 22 mo runway
- Dec2027
estimated
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Hepatocellular Carcinoma · Biliary Tract Cancer
NCT05733598Cash to the catalyst, barely$308M cash · 15 mo runway
- Dec2027
estimated
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Overweight and Obesity
NCT06842186Cash past the catalyst$431M cash · 25 mo runway
- Dec2027
estimated
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Advanced Solid Tumors
NCT06795412Cash runs out first$55.6M cash · 9.4 mo runway
- Dec2027
estimated
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
Immunoglobulin A Nephropathy
NCT07890909Self-funding$9.82B cash · Self-funding runway
- Dec2027
estimated
Self-funding$3.59B cash · Self-funding runway
- Dec2027
estimated
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy · hATTR-PN
NCT07223203Self-funding$3.59B cash · Self-funding runway
- Dec2027
estimated
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Glycogen Storage Disease Type Ia
NCT06735755Cash past the catalyst$1.04B cash · 32 mo runway
- Dec2027
estimated
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Duchenne Muscular Dystrophy
NCT04626674Self-funding$934M cash · Self-funding runway
- Dec2027
estimated
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
Diabetes Mellitus, Type 1 · Impaired Hypoglycemic Awareness · Severe Hypoglycemia
NCT04786262Self-funding$9.82B cash · Self-funding runway
Q1 2028
13 catalysts- Jan2028
estimated
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Multiple Myeloma, Refractory
NCT04414475Cash runs out first$65.1M cash · 12 mo runway
- Jan2028
estimated
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
Phenylketonuria
NCT07241234Cash past the catalyst$907M cash · 33 mo runway
- Jan2028
estimated
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Graves' Disease
NCT07722546Self-funding$1.30B cash · Self-funding runway
- Feb2028
estimated
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
IgA Nephropathy · Lupus Nephritis (LN) · C3 (Complement Component 3) Glomerulopathy
NCT06419205Self-funding$159M cash · Self-funding runway
- Feb2028
estimated
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Sickle Cell Disease
NCT05456880Cash past the catalyst$1.04B cash · 32 mo runway
- Feb2028
estimated
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Obesity · Overweight
NCT07284875Cash past the catalyst$1.04B cash · 40 mo runway
- Feb2028
estimated
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
End Stage Renal Disease · Renal Impairment · Obesity
NCT07793929Cash past the catalyst$1.04B cash · 40 mo runway
- Mar2028
estimated
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma
NCT07807163Cash past the catalyst$497M cash · 44 mo runway
- Mar2028
estimated
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Obesity
NCT07284979Cash past the catalyst$1.04B cash · 40 mo runway
- Mar2028
estimated
Self-funding$710M cash · Self-funding runway
- Mar2028
estimated
Cash to the catalyst, barely$349M cash · 21 mo runway
- Mar2028
estimated
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Obesity With Diabetes · Overweight With Diabetes
NCT07284901Cash past the catalyst$1.04B cash · 40 mo runway
- Mar2028
estimated
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
NCT06679946Self-funding$3.59B cash · Self-funding runway
Q2 2028
7 catalysts- Apr2028
estimated
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Hypertension
NCT07553442Self-funding$3.59B cash · Self-funding runway
- Apr2028
estimated
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma
NCT06788990Cash past the catalyst$497M cash · 44 mo runway
- Apr2028
estimated
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Gastroesophageal Cancer (GC) · Hepatocellular Carcinoma (HCC) · Endometrial Cancer
NCT07419841Cash past the catalyst$180M cash · 38 mo runway
- Apr2028
estimated
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Hypothalamic Obesity
NCT07156578Cash past the catalyst$321M cash · 47 mo runway
- Apr2028
estimated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive Tumor
NCT06982521Cash past the catalyst$849M cash · 48 mo runway
- May2028
estimated
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Alpha 1-Antitrypsin Deficiency
NCT06389877Cash past the catalyst$1.04B cash · 32 mo runway
- May2028
estimated
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Advanced Solid Tumor, Adult · ERBB2 Altered Breast Cancer · ERBB2 Gene Amplification
NCT07361562Cash past the catalyst$792M cash · 31 mo runway
Readout dates are sponsor-supplied primary completion dates from ClinicalTrials.gov and move as enrollment moves. FDA dates are PDUFA target action dates the company stated in its own 8-K, 10-Q or 10-K, linked to the filing. The funding verdict compares the company’s runway, derived from its filed cash flow statements, with the months remaining to that date; it is an outside estimate, not the company’s own guidance, and it is not investment advice.